Last reviewed · How we verify
Mosquito-bite CHMI
At a glance
| Generic name | Mosquito-bite CHMI |
|---|---|
| Sponsor | Sanaria Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites (PHASE1)
- Durability of Protection After Single Immunisation With GA2 Sporozoites (CoGA-Rechallenge) (PHASE1)
- Trial to Evaluate L9LS in Healthy Adults (PHASE1)
- Trial to Evaluate CIS43LS in Healthy Adults (PHASE1)
- VAC 072-An Efficacy Study of R21/MM in Different Dose Schedules (PHASE1, PHASE2)
- Evaluate the Infectivity Equivalence of Current and New Lots of Plasmodium Falciparum Strain NF54 (PHASE1)
- Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 (NA)
- Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mosquito-bite CHMI CI brief — competitive landscape report
- Mosquito-bite CHMI updates RSS · CI watch RSS
- Sanaria Inc. portfolio CI